Gary Gibson, Ph.D., Director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at the Burke Medical Research Institute was featured on Wall Street Journal Live on Tuesday.
On the program, Dr. Gibson discussed a clinical trial currently being conducted at BMRI for people with mild Alzheimer’s disease or mild cognitive impairment. The study aims to determine if increasing brain thiamine through the use of the drug benfotiamine can help slow cognitive decline.
The trial is being funded by the National Institutes of Health and the Alzheimer’s Drug Discovery Foundation and is currently recruiting participants. Additional investigators on the study include Barry D. Jordan, M.D., MPH, Pasquale Fonzetti M.D., Ph.D., Rosanna Cirio, BS, MS and Jessica Franchino-Elder Ph.D. If you think you or your loved one may qualify for the study, click here.